At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 67 enrolled
Drug / intervention
Pioglitazone +1 moredrug
Likely dose
Pioglitazone 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Pioglitazone on Stress Reactivity and Alcohol Craving
The University of Texas Health Science Center, Houston·interventional·Posted Nov 4, 2021·Updated Aug 27, 2025
In Brief
A Phase 2 clinical trial evaluating Pioglitazone and Placebo for Alcohol Use Disorder. Completed, enrolled 67 participants across 1 site.
Detailed Summary
The purpose of this study is to examine the effects of pioglitazone on stress-induced relapse risk in a laboratory model and to examine the effects of pioglitazone on drinking, stress/anxiety, and alcohol craving in the natural environment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorder
CountriesUnited States
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartMay 2022
Primary CompletionAug 2024
TodayJul 2026
First PostedNov 4, 2021
Enrollment StartMay 12, 2022
Primary CompletionAug 16, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.7 years ago
Interventions
Pioglitazonedrug
For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by end of week 1, which is within standard titration parameters as per the investigator's brochure.
Placebodrug
Pill capsules will look same as that of active drug.